Low Breast Density, Poor Breast Cancer Prognosis
Patients with breast cancer and very low mammographic breast density have a poorer prognosis.
Very low mammographic breast density is associated with higher tumor grade and predicted worse survival, according to a study published in the journal European Radiology.
Researchers from Finland examined the prognostic value of mammographic breast density (MBD) and any relationship with established prognostic factors in patients with invasive breast cancer.
The study included 270 women with breast cancer. The researchers classified MBD according to percentile density: <5%, 5%–10%, 10%–25%, 25%–50%, 50%–75%, and >75%. The cases were also categorized into very low density (VLD; <10%), low density (LOD; <25%) and mixed density (MID; >25%).
The researchers found that MBD was inversely associated with tumor grade. Patients with LOD breasts had worse prognoses compared to those with MID breasts.
The strongest significance was seen among patients with VLD breasts compared to the remaining patients. No other mammographic feature was prognostically significant.
"It is difficult to detect small tumors when screening dense breasts, and this results in a higher occurrence of clinically detectable interval cancers,” Professor Ritva Vanninen, said in a release. “In the U.S., it is nowadays mandatory to let patients know if they have dense breast tissue. This allows them to choose whether they wish to have further tests, for example a screening ultrasound."
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
